<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20698">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02837445</url>
  </required_header>
  <id_info>
    <org_study_id>CS-03</org_study_id>
    <nct_id>NCT02837445</nct_id>
  </id_info>
  <brief_title>Moderato System: A Double-Blind Randomized Trial</brief_title>
  <official_title>Clinical Evaluation of Safety and Effectiveness of the BackBeat Medical Moderato System in Patients With Hypertension: A Double-Blind Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BackBeat Medical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MGH Echo Core Lab</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MLM Medical Labs GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>nabios GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>BackBeat Medical Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this double blind randomized study is the evaluation of the safety and
      efficacy of the Moderato System. The Moderato pacemaker is indicated for patients who
      require a dual chamber pacemaker and also have hypertension, in order to reduce their blood
      pressure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of composite of major cardiac events</measure>
    <time_frame>6 months post Randomization</time_frame>
    <description>including heart failure, clinically significant arrhythmias eg, persistent or increased atrial fibrillation, serious ventricular arrhythmias, myocardial infarction, stroke, heart failure, renal failure and/or related safety events that result in death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in average 24 hour systolic ambulatory blood pressure</measure>
    <time_frame>Week 3 pre Randomization and 6 months post Randomization</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Hypertension Resistant to Conventional Therapy</condition>
  <condition>Bradycardia</condition>
  <condition>Atrioventricular Block</condition>
  <arm_group>
    <arm_group_label>BackBeat-PHC ON</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible patients randomized after optimization phase to PHC ON for 6 months Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control or BackBeat PHC OFF</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible patients randomized after optimization phase to pacemaker only (PHC OFF) for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BackBeat-PHC ON</intervention_name>
    <description>Eligible patients randomized after optimization phase to PHC ON for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator</description>
    <arm_group_label>BackBeat-PHC ON</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BackBeat-PHC OFF</intervention_name>
    <description>Eligible patients randomized after optimization phase to PHC OFF for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.</description>
    <arm_group_label>Control or BackBeat PHC OFF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Requirement of dual chamber pacemaker.

          -  Stable (at least 1 month) hypertension treatment with at least 1 anti-hypertensive
             drug, which is anticipated to be maintained for at least 7 months.

          -  Average day time (7AM-10PM) ambulatory systolic blood pressure ≥ 130 mmHg and office
             blood pressure ≥140 mmHg.

          -  Subject lives in the proximity of the study center, which will permit compliance with
             study visits for at least 7 months.

        Exclusion Criteria:

          -  Known secondary cause of HTN.

          -  Average ambulatory or office systolic BP &gt; 195 mmHg.

          -  Permanent atrial fibrillation.

          -  History of significant paroxysmal atrial fibrillation/flutter burden (defined as &gt;25%
             of beats).

          -  Cardiac ejection fraction &lt;50%.

          -  Symptoms of heart failure, NYHA Class II or greater.

          -  Hypertrophic cardiomyopathy, restrictive cardiomyopathy or inter-ventricular septal
             thickness ≥ 15 mm.

          -  Subject is on dialysis.

          -  Subject has an estimated Glomerular Filtration Rate &lt; 30 ml/min/1.73 m²

          -  Prior neurological events (stroke or TIA) within the past year or events at a prior
             time that has resulted in residual neurologic deficit.

          -  Carotid artery disease.

          -  Known autonomic dysfunction.

          -  History of clinically significant uncontrolled ventricular tachyarrhythmia or has
             experienced sudden death.

          -  Previous active device-based treatment for HTN.

          -  Existing implant, other than a pacemaker that needs replacing.

          -  Subject is or has the possibility of becoming pregnant and is unwilling of
             contraception during the study.

          -  Subject is unwilling or cannot provide Informed Consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl-Heinz Kuck, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asklepios Klinik St. Georg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuval Mika, Ph.D.</last_name>
    <phone>+1856912155</phone>
    <email>ymika@backbeatmedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ricardo Aviv, Ph.D.</last_name>
    <phone>+4915123684503</phone>
    <email>raviv@backbeatmedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Krankenhaus der Elisabethinen</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josef Aichinger, Prim. Mag.</last_name>
      <email>josef.aichinger@elisabethinen.or.at</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Sturmberger, Dr. med.</last_name>
      <email>Thomas.Sturmberger@elisabethinen.or.at</email>
    </contact_backup>
    <investigator>
      <last_name>Josef Aichinger, Prim. Mag.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Sturmberger, Dr. med</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Pezawas, Prof.</last_name>
      <email>Thomas.Pezawas@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Thomas Pezawas, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OLV Hospital Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Riet Dierckx, MD</last_name>
    </contact>
    <investigator>
      <last_name>Riet Dierckx, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Brussel - Heart Rhythm Management Center</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo de Asmundis, Prof.</last_name>
      <phone>02 476 37 04</phone>
      <email>carlo.deasmundis@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Carlo de Asmundis, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Prague</city>
        <zip>15030</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petr Neuzil, Prof.</last_name>
      <email>PNeuzil@seznam.cz</email>
    </contact>
    <investigator>
      <last_name>Petr Neuzil, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Semmelweis University Heart and Vascular Center</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Béla Merkely, Prof.</last_name>
      <email>merkely.bela@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Béla Merkely, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>P. Stradins Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrejs Erglis, Prof.</last_name>
      <email>a.a.erglis@stradini.lv</email>
    </contact>
    <investigator>
      <last_name>Andrejs Erglis, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of Lithuanian University of Health Science Kauno Klinikos</name>
      <address>
        <city>Kaunas</city>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aras Puodziukynas, Prof.</last_name>
      <email>aras.puodziukynas@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Aras Puodziukynas, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital Santariskiu Klinikos</name>
      <address>
        <city>Vilnius</city>
        <zip>08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Germanas Marinskis, Prof.</last_name>
      <email>Germanas.Marinskis@santa.lt</email>
    </contact>
    <investigator>
      <last_name>Germanas Marinskis, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital, University Hospital Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth F Greenwood, MSc</last_name>
      <phone>+44 8120 8292</phone>
      <email>Elizabeth.greenwood@uhs.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Lisa L Fletcher, MSc</last_name>
      <phone>+44 8120 8646</phone>
      <email>Lisa.fletcher@uhs.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>John R Paisey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medway NHS Foundation Trust</name>
      <address>
        <city>Gillingham</city>
        <state>Kent</state>
        <zip>ME7 5NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maines Msiska, BSc Hons</last_name>
      <phone>01634830000</phone>
      <phone_ext>5437</phone_ext>
      <email>Maines.Msiska@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Abimbola Ojo, MPhil</last_name>
      <phone>01634830000</phone>
      <phone_ext>5906</phone_ext>
      <email>abimbola.ojo@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Shaumik Adhya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Thomas Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emma Ms Atkinson</last_name>
      <phone>0207 188 0998</phone>
      <email>emma.atkinson@gstt.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Karen Ms Wilson</last_name>
      <phone>0207 188 9435</phone>
      <email>karen.wilson@gstt.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Aldo Dr Rinaldi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 10, 2017</lastchanged_date>
  <firstreceived_date>July 8, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Bradycardia</mesh_term>
    <mesh_term>Atrioventricular Block</mesh_term>
    <mesh_term>Coronary Vasospasm</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
